CRBU
Caribou Biosciences Inc

2,696
Mkt Cap
$177.59M
Volume
1.15M
52W High
$3.54
52W Low
$0.66
PE Ratio
-1.12
CRBU Fundamentals
Price
$1.84
Prev Close
$1.90
Open
$1.78
50D MA
$1.64
Beta
1.84
Avg. Volume
1.05M
EPS (Annual)
-$1.65
P/B
1.25
Rev/Employee
$67,986.40
$39.43
Loading...
Loading...
News
all
press releases
Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates
Urogen Pharma (URGN) delivered earnings and revenue surprises of +18.18% and +6.42%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·18h ago
News Placeholder
More News
News Placeholder
Caribou Biosciences (CRBU) to Release Earnings on Monday
Caribou Biosciences (NASDAQ:CRBU) will be releasing its Q4 2025 earnings before the market opens on Monday, March 9. (View Earnings Report at...
MarketBeat·1d ago
News Placeholder
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of -21.88% and +10.21%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Caribou Biosciences (NASDAQ:CRBU) Insider Sells $13,598.48 in Stock
Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) insider Ruhi Ahmad Khan sold 6,938 shares of the stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price...
MarketBeat·6d ago
News Placeholder
Caribou Biosciences (NASDAQ:CRBU) Insider Ruhi Ahmad Khan Sells 6,938 Shares
Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) insider Ruhi Ahmad Khan sold 6,938 shares of the firm's stock in a transaction on Tuesday, February 24th. The shares were sold at an average...
MarketBeat·6d ago
News Placeholder
Insider Selling: Caribou Biosciences (NASDAQ:CRBU) Insider Sells 6,938 Shares of Stock
Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) insider Barbara Mcclung sold 6,938 shares of the firm's stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at...
MarketBeat·6d ago
News Placeholder
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of +26.89% and +243.23%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
Caribou Biosciences Details Pivotal-Ready Vispa-cel Plan, Flags Need for More Capital at Citi Summit
Caribou Biosciences (NASDAQ:CRBU) executives used Citi's Virtual Oncology Summit for 2026 to outline the company's strategy for bringing off-the-shelf, allogeneic CAR-T cell therapies to broader...
MarketBeat·8d ago
News Placeholder
Genomics Stocks That Deserve a Place in Your Portfolio in 2026
Genomics and synthetic biology are reshaping healthcare, as rapid DNA sequencing advances power personalized medicine and strong market growth.
Zacks·11d ago
News Placeholder
Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year?
Here is how Biohaven Ltd. (BHVN) and Caribou Biosciences, Inc. (CRBU) have performed compared to their sector so far this year.
Zacks·21d ago
<
1
2
...
>

Latest CRBU News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.